Paratek Pharmaceuticals Opens New Corporate Headquarters in Boston
News Jul 24, 2015
Paratek Pharmaceuticals, Inc. has opened its new corporate headquarters in Boston at 75 Park Plaza.
"This move comes at an important time for Paratek, as we have recently initiated a global Phase 3 program for our lead antibiotic compound, omadacycline. With two important products in Phase 3 clinical studies, we are now preparing for the next phase of our growth as a biopharmaceutical company," said Michael Bigham, Chairman and Chief Executive Officer, Paratek. "The Company takes pride in its origins as a Boston-based biopharmaceutical company, and we look forward to our continued growth here in Boston."
The address of the new headquarters is 75 Park Plaza, 4th floor, Boston, MA 02116. Paratek was previously located at 75 Kneeland Street in Boston. In June Paratek opened a second office location in the Philadelphia area.
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE
Vapourtec Collaboration with NPM Drives New Flow TechnologyNews
Flow chemistry engineering specialists Vapourtec (UK) have been engaged in a successful collaboration with New Path Molecular Research Ltd (NPM), focusing on the development of new reactor technology and methods for peptide synthesis.READ MORE